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Abstract
Inspiratory muscle weakness in patients w ith COPD is o f major clinical relevance. For instance, 
maximum inspiratory pressure generation is an independent determinant o f survival in severe 
COPD. Traditionally, inspiratory muscle weakness has been ascribed to  hyperinflation-induced 
diaphragm shortening. However, more recently, invasive evaluation o f diaphragm contractile 
function, structure, and biochemistry demonstrated that cellular and molecular alterations occur, 
o f which several can be considered pathologic o f nature. Whereas the fiber type shift towards 
oxidative type I fibers in COPD diaphragm is regarded beneficial, rendering the overloaded 
diaphragm more resistant to  fatigue, the reduction o f diaphragm fiber force generation in vitro likely 
contributes to  diaphragm weakness. The reduced diaphragm force generation at single fiber level 
is associated w ith loss o f myosin content in these fibers. Moreover, the diaphragm in COPD is 
exposed to  oxidative stress and sarcomeric injury. This review postulates that the oxidative stress 
and sarcomeric injury activate proteolytic machinery, leading to  contractile protein wasting and, 
consequently, loss o f force generating capacity o f diaphragm fibers in patients w ith  COPD. 
Interestingly, several o f these presumed pathologic alterations are already present early in the 
course o f the disease (G O LD I/II), although these patients appear not limited in the ir daily life 
activities. Treatment o f diaphragm dysfunction in COPD is complex since its etiology is unclear, but 
recent findings indicate the ubiquitin-proteasome pathway as a prime target to  attenuate diaphragm 
wasting in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) has been 
predicted to become the third leading cause of death and 
the fifth commonest cause of disability in the world by 
2020 [1]. Today it is recognized that COPD affects func­
tion of other organs besides the lungs. In particular, dys­
function of the respiratory muscles has been shown to 
occur in patients with COPD. Dyspnea is the most disa­
bling symptom in patients with COPD, and could result
from a decreased capacity of the respiratory muscles to 
meet an increased mechanical load. Hypercapnic respira­
tory failure due to inspiratory muscle weakness [2] is asso­
ciated with morbidity in these patients [3], and maximum 
inspiratory pressure is an independent determinant of sur­
vival in these patients [4]. These studies stress the impor­
tance of inspiratory muscle dysfunction in patients with 
COPD. Accordingly, the interest in defining the underly-
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ing causes of inspiratory muscle weakness in COPD has 
increased over the recent years.
The majority of studies dealing with factors contributing 
to inspiratory muscle weakness in COPD has focused on 
the diaphragm, mainly because the diaphragm is the prin­
ciple muscle of inspiration. Patients with COPD have a 
lower transdiaphragmatic pressure generating capacity 
than healthy subjects [5], which has been ascribed to 
hyperinflation-induced diaphragm shortening, placing 
the diaphragm at a mechanical disadvantage [6]. When 
compensated for reduced muscle length, diaphragm func­
tion was suggested to be preserved or even improved in 
severe COPD [7]. However, the invasive evaluation of the 
human diaphragm has accelerated the understanding of 
the pathogenesis of diaphragm weakness in COPD. Since 
the late nineties an increasing number of papers has been 
published describing altered functional, structural and 
metabolic characteristics in diaphragm biopsies of 
patients with COPD [8-21]. Importantly, several of these 
changes occur already early in the course of the disease 
[11,12,18,19,21] and show a strong negative correlation 
with respiratory muscle strength [14,17]. Together these 
findings point towards a new concept in which the patho­
genesis of inspiratory muscle dysfunction in COPD is 
related to cellular and molecular changes within the dia­
phragm, and occurs much earlier as previously assumed.
The aim of the present paper is to review the current 
knowledge on the effect of COPD on the human dia­
phragm, and to generate a hypothesis for further research. 
First, diaphragm performance in vivo will be discussed 
briefly. Second, studies describing changes in the dia­
phragm will be reviewed. Finally, potential causes for the 
observed cellular and molecular changes in COPD dia­
phragm will be addressed.
Diaphragm performance in CO PD: in vivo studies
Diaphragm performance is mainly characterized by its 
strength and endurance. Strength is defined as the capac­
ity of the muscle to generate force and endurance is 
defined as the capacity of the muscle to maintain a certain 
force over time, in other words, to resist fatigue. Loss in 
either strength or endurance results in diaphragm weak­
ness and impaired performance.
Force generation of the diaphragm in vivo is determined 
by central drive, phrenic nerve conductance, neuromuscu­
lar transmission and excitation-contraction coupling. 
Direct determination of diaphragm muscle force generat­
ing capacity in vivo is not possible. Instead the capacity of 
the inspiratory muscles to generate negative intrathoracic 
or transdiaphragmatic pressure is usually determined, and 
used as a measure for respiratory muscle strength. How­
ever, it should be emphasized that these methods do not
solely depend on muscle function, but on motivation, 
central drive and nerve function as well.
It has been consistently demonstrated that patients with 
severe COPD generate less maximal inspiratory pressure 
and transdiaphragmatic pressure by voluntary manoeu­
vres, but also by phrenic nerve stimulation (ruling out 
effects of central drive), compared to patients without 
COPD [5,7,22-24]. Therefore, strength is regarded as a 
limiting factor in diaphragm performance in COPD. 
Indeed, inspiratory muscle weakness was shown to be 
related to dyspnea [25], and maximal inspiratory pressure 
is an independent determinant of survival in COPD [4]. 
Previous work by Similowski and co-workers [7] sug­
gested that weakness of the diaphragm could be explained 
by hyperinflation-induced diaphragm shortening, which 
places the diaphragm on a suboptimal position on its 
force-length relationship. They revealed that at equivalent 
lung volumes, the generated transdiaphragmatic pressures 
were even higher in some patients with COPD compared 
to healthy subjects. However, in addition to a mechanical 
explanation for diaphragm weakness in COPD, several 
studies proposed structural adaptations in the diaphragm 
to be at play. For instance, parallel reductions of inspira­
tory and expiratory pressures are described in moderate- 
to-severe COPD patients [26,27]. Since the expiratory 
muscles are not at a mechanical disadvantage, these find­
ings suggest that some COPD patients have generalized 
diaphragm weakness. This notion is supported by the 
high correlation between maximal inspiratory and expira­
tory pressures in their COPD patients [26].
The present data dealing with diaphragm endurance in 
COPD are limited, mainly because endurance tests are dif­
ficult to perform and interpret (for instance, diaphragm 
endurance tests imply normalized patient stimulation 
and a high degree of patient motivation). Newell et al. [5] 
tested diaphragm endurance by measuring pressure out­
put during repeated maximal voluntary contractions of 
the inspiratory muscles. During the endurance sequence 
the decline in pressure was less in patients with severe 
COPD compared to individuals with normal lung func­
tion. Later, these findings were confirmed by other studies 
in patients with moderate-to-severe COPD [28,29]. So, 
despite the greater load and recruitment, diaphragm 
endurance appears to be increased in COPD. This is at 
least partly accounted for by diaphragm remodelling 
[15,16] and a shorter respiratory duty cycle [30]. For a 
review on this topic see Laghi and Tobin [6].
Cellular and molecular changes in the diaphragm in COPD
In the last decade, several studies were published investi­
gating diaphragm biopsies from both patients with and 
without COPD. The obtained diaphragm specimens 
allowed the evaluation of functional, structural and meta­
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bolic changes in diaphragm fibers of COPD patients. 
These studies improved the understanding of the effects of 
COPD on respiratory muscle performance.
Diaphragm fiber type distribution
A consistent alteration in the diaphragm of COPD 
patients is a fiber type shift towards more oxidative, type 
I, fibers.
Fiber typing can be performed histochemically by staining 
myofibrillar ATPase (type I, Ila, and IIx) [31] or by deter­
mination of mitochondrial enzyme activity (slow-twitch 
oxidative, fast-twitch oxidative-glycolytic, and fast-twith 
glycolytic) [32]. More recently, myofibrillar ATPase stain­
ing was shown to correspond to the expression of differ­
ent myosin heavy chain isoforms (MHCslow, MHC2A, 
MHC2B and MHC2X), that can be identified by immunore- 
activity to specific antibodies and/or by protein electro­
phoresis [33]. Type I fibers have a slow twitch, and 
depend mainly on aerobic metabolism and are therefore 
fatigue resistant. In contrast, type IIx fibers have a fast 
twitch and their metabolism is anaerobic glycolytic, 
which renders them susceptible for fatigue. Type IIa fibers 
have intermediate properties; they do have a fast twitch 
but are capable of working under both aerobic and anaer­
obic conditions and are therefore relatively fatigue-resist­
ant. Maximal tension development of mammalian muscle 
is dependent on fiber type, with the lowest tension devel­
oped by type I fibers and the highest tension by type IIx 
fibers. However, in humans this fiber type-dependency of 
tension generating capacity is less obvious (for review see 
Bottinelli and Reggiani [34]).
The human diaphragm is chronically active and is among 
the most aerobicaly adapted striated muscles. Indeed, in 
individuals with normal lung function the diaphragm 
consists of a relatively high proportion (~50%) of type I 
fibers, compared to type IIa (~30%) and IIx (~20%) fibers 
[15,35,36]. In patients with COPD, the diaphragm works 
against an increased work load due to airflow limitation 
and geometrical changes in the thorax as a result of pul­
monary hyperinflation. It has been hypothesized that the 
increased workload emulates endurance training of the 
diaphragm in these patients. In line with this, Levine and 
coworkers found an increased proportion of type I fibers 
in the diaphragm of patients with severe COPD, whereas 
the proportion of fast, fatiguing fibers (type II) was 
decreased [15] (figure 1). These findings were confirmed 
by other studies in patients with severe [13,17,35,37-39], 
but also mild-to-moderate COPD [19,21]. Several studies 
have shown that other inspiratory muscles, such as the 
external intercostal muscles, do not exhibit a fiber type 
shift in either direction in patients with moderate [40] 
and severe COPD [38]. The shift from type II towards type
Non-COFD COPD
F ig u re  1
Myosin heavy chain isoform distribution, analyzed by western 
blot, in the costal diaphragm from  severe COPD and non- 
COPD patients. Diaphragm from  COPD patients contains a 
higher proportion o f slow myosin heavy chain isoform and 
low er proportions o f IIA and IIX isoforms compared to  the 
diaphragm from  non-COPD patients. Reproduced from  Lev­
ine et al. [ l5 ]  w ith  permission.
I fibers is regarded as beneficial as it may render the COPD 
diaphragm more resistant to fatigue [15].
Besides a shift towards type-I fibers, the diaphragm in 
severe COPD is characterized by a fast-to-slow shift of the 
sarcoplasmic reticulum calcium-ATPase (SERCA), as 
shown by Nguyen et al. [39]. In addition, the content of 
the fast SERCA-isoform was decreased. SERCAs pump cal­
cium from the myoplasm into the sarcoplasmic reticulum 
and thereby initiate striated muscle relaxation. Although 
not studied, reduced SERCA pumping and the resulting 
slower relaxation could affect the force-frequency charac­
teristics of diaphragm fibers in COPD. First, for a given 
level of force generation a lower stimulation frequency is 
needed. Second, lower stimulation frequencies will 
reduce the energetic cost of calcium pumping in COPD 
diaphragm fibers and thereby increase efficiency.
Diaphragm metabolism
Force generation by striated muscle is powered by adeno­
sine triphosphate (ATP), a 'high energy' compound. Curi­
ously, for such an important substance as ATP, it is found 
in relatively low concentrations within cells. Striated mus­
cle, and especially the diaphragm with its high duty cycle, 
has a high metabolic rate and would use up the available 
ATP in a few seconds if it was not rapidly regenerated. ATP 
generation in striated muscle occurs via aerobic and 
anaerobic enzymatic pathways. In vitro determination of
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enzyme activities involved in muscle metabolism pro­
vides information regarding changes in expression of pro­
teins involved in these metabolic pathways. Typical 
anaerobic enzymes are phophorylase, hexokinase and lac­
tate dehydrogenase (LDH), which are mainly present in 
the cytosol. Typical aerobic enzymes are succinic dehydro­
genase (SDH) citrate synthase (CS) and L(+)3-hydroacyl- 
CoA-dehydrogenase (HADH), which are mainly 
mitochondria-associated.
As mentioned previously, the different fiber types have 
distinct metabolic properties. Therefore, the shift towards 
type I fibers in COPD diaphragm is expected to result in 
an increased oxidative capacity. Indeed, it is well estab­
lished that the activity of oxidative enzymes is increased in 
COPD diaphragm, with a concomitant decrease in glyco­
lytic enzyme activities.
Several labs have reported increased activity of the oxida­
tive enzymes CS, SDH and HADH in the diaphragm of 
patients with COPD [13,19,41], whereas the activities of 
the glycolytic enzymes hexokinase and LDH were 
decreased [42]. Similar to the fiber type shift, the changes 
in enzyme activities were present in some patients with 
only moderate COPD [19,42]. In addition to changes in 
enzyme activities, the mitochondrial oxidative capacity 
relative to ATP demand appears increased in the dia­
phragm of patients with severe COPD [13]. Also, 
enhanced function of the mitochondrial electron trans­
port chain in the diaphragm of severe COPD patients has 
been reported [38]. Increased maximal mitochondrial res­
piration, and improved coupling of oxidation to phos­
phorylation was found in COPD diaphragm. In addition, 
these changes were associated with increase of CS activity. 
It was proposed that the increased mitochondrial effi­
ciency in ATP production was the result of changed per­
meability of the inner mitochondrial membrane, thereby 
decreasing proton leak and basal respiration [38]. In 
patients with moderate COPD no changes in diaphragm 
mitochondrial efficiency were found [41] compared to 
healthy subjects.
Together these data indicate that the changes in oxidative 
capacity and mitochondrial function in the diaphragm 
occur in line with the progression of COPD and the con­
comitant shift towards more oxidative type I fibers. In 
other respiratory muscles, such as the external intercos- 
tals, the increase in oxidative capacity associated with 
COPD, appears to be less pronounced [38]. This was, at 
least in part, explained by the absence of a fiber type shift 
in these muscles.
Functional changes: diaphragm single fiber studies 
Single fiber contractile properties
Recent data from Levine and co-workers [14], and our 
group [18], indicate impaired contractile protein function 
in diaphragm fibers from patients with COPD. These 
studies evaluated the contractility of permeabilized 
(skinned) single fibers dissected from diaphragm biopsies 
obtained during thoracotomy. These biopsies do not 
allow dissection of muscle fibers from tendon to tendon. 
Thus fiber ends are not sealed, which disrupts normal 
excitation-contraction coupling. However, the skinned 
fiber model provides an excellent model for direct evalua­
tion of contractile protein function in these fibers. In 
skinned fibers, the membranous structures, such as the 
sarcolemma, sarcoplasmic reticulum and mitochondria, 
are made highly permeable. This procedure leaves the 
contractile proteins intact. Therefore, a skinned fiber can 
be regarded as a collection of functionally isolated sar­
comeres in series and in parallel. Mounting of skinned fib­
ers between a force transducer and a length motor and 
subsequent exposure of the fiber to calcium enables eval­
uation of contractile protein function. Recent data from 
our lab [18] showed markedly reduced maximum force 
generation of diaphragm fibers from patients with only 
mild-to-moderate COPD compared to non-COPD 
patients. (figure 2) The maximum force generated by a 
muscle fiber is strongly dependent on the content of 
myosin, the main contractile protein (figure 3). The 
reduction of maximum force generated by COPD dia­
phragm fibers, as observed in our study, was associated 
with loss of myosin content in these fibers [18]. On the 
basis of their single fiber data, Levine et al. [15] calculated 
that patients with severe COPD would generate only 60%
nmCOPD
COPD
slew 2A
it^osin heavy chain isoiomi
F ig u re 2
Maximum force generation o f skinned diaphragm fibers from 
non-COPD and m ild-to-moderate COPD patients. Maximum 
force, normalized to  cross sectional area, o f single fibers 
from  COPD patients was low er in type slow and 2A fibers 
compared to  non-COPD patients. Data are presented as 
model estimates ± sem. *: P < 0.05 different from  non- 
COPD group. Reproduced from Ottenheijm et al. [18] w ith 
permission.
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F ig u re 3
Top: Simplified model o f tw o  muscle sarcomeres in parallel. The sarcomere is comprised o f the thin (mostly actin) filaments, 
the thick (mostly myosin) filaments, and the giant filamentous molecule titin . The thin filaments are anchored in the Z-line, 
where they are cross-linked by a-actinin. The thick filament is centrally located in the sarcomere and constitue the sarcomeric 
A-band. The myosin heads, o r  cross-bridges, on the th ick filament interact w ith actin during activation. Titin spans the half-sar- 
comeric distance from  the Z-line to  the M-line, thus forming a th ird  sarcomeric filament. In the I-band region, titin  is extensible 
and functions as a molecular spring that develops passive tension upon stretch. In the A-band titin  is inextensible due to  its 
strong interaction w ith the th ick filament.Bottom: Electronmiscroscopic photograph o f the ultrastructural organization o f sar­
comeres in parallel.
of the average maximal transdiaphragmatic specific force 
compared to individuals with normal lung function. 
Because maximal transdiaphragmatic pressures of severe 
COPD patients are reduced to approximately 65% of con­
trol values [7,22-24], they proposed that changes at the 
cellular and molecular level in the diaphragm of COPD 
patients can fully account for the reduced diaphragm 
strength in vivo in these patients [14].
It should be noted however, that in vivo the diaphragm 
shortens against a submaximal load rather than that it per­
forms maximum isometric contractions. Thus, submaxi­
mal and kinetic parameters of muscle function provide 
important physiological information. We found that at a 
certain calcium concentration, the generated force relative 
to maximum force, is less in fibers from COPD patients 
compared to non-COPD patients [18]. In other words, the 
calcium sensitivity of force generation is reduced. This 
appears to be an important finding, as it could compro­
mise diaphragm function at submaximum activation in 
vivo. Moreover, diaphragm fibers from COPD patients 
had slower attachment/detachment rates of myosin to
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actin during activation [18]. These data show that, besides 
loss of contractile protein in the diaphragm of patients 
with mild-to-moderate COPD, the remaining contractile 
proteins are dysfunctional. The molecular basis of this 
protein dysfunction is unclear. However, probably 
myosin and troponin are involved, as the functioning of 
these proteins is an important determinant of myosin­
actin attachment/detachment rates and calcium sensitiv­
ity of force generation.
Single fiber passive properties
For optimal contractile function, besides contractile pro­
teins such as myosin, passive-elastic structures in the sar­
comere are needed [43]; deletion of these structures 
abolishes both passive and active force generation by sin­
gle muscle fibers [43]. Therefore, in addition to active 
force generation, passive force characteristics of muscle 
fibers provide important information on muscle function. 
Recently, we [21], and others [12], demonstrated that dia­
phragm fibers from patients with mild-to-moderate 
COPD generate less passive tension upon fiber-stretch 
compared to fibers from patients without COPD. Passive 
tension in these fibers is mainly determined by the prop­
erties of titin [44,45]. Titin spans the half-sarcomeric dis­
tance from the Z-line to the M-line, thus forming a third 
sarcomeric filament, apart from the thick (mostly myosin) 
and thin (mostly actin) filaments [46]. In the I-band 
region, titin is extensible (due to its elastic PEVK segment) 
and functions as a molecular spring that develops passive 
tension upon stretch. Titin gene transcript studies revealed 
increased expression of exons coding for the spring ele­
ments in the elastic region of titin in COPD diaphragm 
[21], most likely resulting in an elongated extensible titin 
segment. (figure 4) These data strongly suggest that alter­
native splicing of the titin gene reduces the passive tension 
generated by diaphragm fibers from COPD patients. In 
contrast to myosin and nebulin content, titin content was 
not reduced in the diaphragm of these patients. Appar­
ently, the diaphragm of patients with mild-to-moderate 
COPD is subject to loss of specific proteins and qualitative 
changes within molecules.
Diaphragm atrophy
Muscle atrophy is defined as the wasting or loss of muscle 
tissue, resulting from an imbalance between protein syn­
thesis and degradation due to disease or deconditioning. 
Atrophy is characterized by a decrease in protein content 
and fiber cross sectional area resulting in reduced force 
production. Diaphragm fiber atrophy is a consistent find­
ing in patients with severe COPD.
Both type I and type II diaphragm fibers show reduced 
cross sectional area in patients with severe COPD com­
pared to non-COPD patients [15,47]. Another study in 
severe COPD patients found reduced cross sectional area
in predominantly type I diaphragm fibers [13]. In contrast 
to patients with severe COPD, reductions in diaphragm 
fiber cross sectional area have not been found in mild or 
moderate COPD patients [16,19,20,48,49]. Although 
these data suggest that fiber atrophy occurs only in severe 
COPD, measuring cross sectional area is not a very sensi­
tive method for detection of atrophy. Indeed, recent data 
show contractile protein loss in the diaphragm in mild-to- 
moderate COPD [11,18,21] (FEV1 ~70% predicted). In 
these patients, the myosin content in both type I and IIa 
diaphragm fibers was markedly reduced, while fiber cross 
sectional area remained normal. Consequently, myosin 
concentration was decreased in these fibers by ~50% [18]. 
As expected, this reduction in myosin content was associ­
ated with decreased maximum force generation in those 
fibers, as discussed earlier.
In general, striated muscle atrophy results from increased 
proteolysis, rather than decreased synthesis [50]. During 
atrophy the bulk of myofibrillar protein degradation 
occurs via the ubiquitin-proteasome pathway [51,52]. 
Proteolysis by the ubiquitin-proteasome pathway is 
highly selective and precisely regulated [53]. Proteins 
degraded via this pathway are labelled first with ubiquitin 
through the action of specific ubiquitin ligases. In general, 
only damaged or misfolded proteins are labelled. Ubiqui- 
tin-conjugated proteins are subsequently recognized, 
bound and degraded by the 20S proteasome [51]. Recent 
work demonstrated activation of the ubiquitin-proteas- 
ome pathway in the diaphragm of patients with mild-to- 
moderate COPD, as indicated by increased proteasome 
activity, elevated mRNA levels of the ubiquitin ligase 
MAFbx [11], and elevated levels of ubiquitin-conjugated 
proteins [18]. Moreover, unpublished data revealed that 
inhibiting proteasome activity in vivo in an animal model 
of COPD partially restored diaphragm myosin content 
and force generation capacity [54]. These findings 
strongly suggest a key role for ubiquitin-proteasome- 
mediated muscle protein degradation in diaphragm weak­
ness in COPD. Activation of the endoprotease caspase-3 is 
an initial step in myofilament proteolysis by cleavage of 
myosin and actin [55]. In this way, activated caspase-3 
yields fragments that are degradable by the ubiquitin-pro- 
teasome pathway. Indeed, caspase-3 activity is increased 
in the diaphragm of patients with mild-to-moderate 
COPD compared to non-COPD patients [11].
Little is known regarding mediators that affect the rate of 
muscle protein synthesis in COPD diaphragm, although 
glycosaminoglycans might be involved. Glycosaminogly- 
cans are linear unbranched polysaccharides, most of 
which are covalently linked to a protein core to form pro­
teoglycans [56]. Depending on the nature of the gly- 
cosaminoglycan-moiety, one can discern heparan sulfate, 
dermatan sulfate, and chondroitin sulfate proteoglycans.
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A: Analysis o f diaphragm transcripts o f all titin's gene exons from  mild-to-moderate COPD and non-COPD patients. A ll exons 
listed are upregulated by at least 3-fold (P < 0.05) in diaphragm from  COPD patients (black bars) when compared w ith dia­
phragm from non-COPD patients (white bars), and code fo r the extensible I-band segment o f titin  (i.e. PEVK segment). B: 
Immuno-fluorescence analysis o f antibody x |56 , directed against the titin  domain encoded by exon 156, and antibody T I2 , 
directed against a titin  domain near the sarcomeric Z-line. Double-staining w ith antibodies x | 56  and T I 2  revealed increased 
staining intensity o f x | 56  in diaphragm cryosections from  patients w ith COPD (green, A-B), whereas staining intensity o f T I2  
was comparable between both patient groups (red, C-D). Bar: 50 |im. Confocal microscopy demonstrated the expected stain­
ing pattern o f both antibodies: red striation patterns o f T I2  indicating the location o f the sarcomeric Z-lines and green stria­
tions o f *156 indicating the extensible titin  regions o f the sarcomere (E-F). Bar: 2.5 |im. Reproduced from  Ottenheijm et al. 
[21] w ith permission.
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Most proteoglycans are found either on the cell surface, or 
in the extracellular matrix [57,58]. In skeletal muscle gly- 
cosaminoglycans are involved in numerous biological 
processes, notably the orchestration of anabolic and cata­
bolic signaling by unique sulfation patterns on the 
heparan sulfate molecule (for review see [59]). Heparan 
sulfate is essential for the activation of individual mem­
bers of several growth factor families, including hepato- 
cyte growth factor and insulin-like growth factor [60-65]. 
The dynamic spatiotemporal expression of proteoglycans 
and heparan sulfate epitopes provides a micro-environ­
ment in which heparan sulfate mediates growth factor 
activity by creating focal differences in concentration and 
by facilitating ligand-receptor interactions [66]. Through 
this modulating effect on growth factors, glycosaminogly- 
cans are instrumental in skeletal muscle protein synthesis 
and regeneration [67-69]. Recent work [10] indicates 
down-regulation of a specific heparan sulfate epitope in 
the diaphragm of patients with COPD. This down-regu­
lated heparan sulfate epitope appeared to be involved in 
the binding of hepatocyte growth factor. As hepatocyte 
growth factor is an important modulator of contractile 
protein synthesis [70], its down-regulation may affect 
contractile protein content in the diaphragm of patients 
with COPD. Interestingly, these changes already occur in 
patients with mild-to-moderate COPD (GOLD stage I/II).
It should be noted that the reduced diaphragm fiber cross 
sectional area in severe COPD, besides compromising dia­
phragm force generation, could also represent a beneficial 
adaptation by facilitating oxygen transport and diffusion 
from the capillaries into the fibers to meet the increased 
oxidative metabolism in COPD diaphragm (as discussed 
earlier). However, previous studies reported comparable 
capillarization between individuals with normal lung 
function and mild-to-moderate [19] and moderate-to- 
severe COPD patients [17], although diaphragmatic 
mRNA levels of vascular endothelial growth factor are 
increased in patients with moderate COPD [71], suggest­
ing enhanced angiogenesis.
Diaphragm injury
Striated muscle injury is characterized by morphological 
abnormalities such as disruption of membranous struc­
tures (sarcolemma, mitochondria etc), degeneration of 
the cytoplasm, and disorganization of the contractile 
apparatus (including sarcomere disruption, Z-line stream­
ing and misalignment of the myofilaments). It is well 
established that exertion can have profound effects on 
striated muscle structure and can induce muscle injury. 
For instance, injury of the diaphragm has been observed 
in several animal models of respiratory loading [72,73]. 
Recent data clearly demonstrate increased diaphragm 
injury in patients with COPD.
Increased sarcomere disruption has been found in the dia­
phragm of patients with moderate-to-severe COPD [8,20] 
(figure 5). The FEV1 was inversely correlated with both sar­
comere disruption density and area fraction [20]. Data 
from our group show Z-band streaming and accumula­
tions of Z-band material in the diaphragm, indicating 
myofibrillar myopathy, in severe COPD [74]. In another 
study in mild-to-moderate COPD patients (average FEV1, 
60% predicted), diaphragm cross sections showed no 
signs of injury, although sarcomere length appeared 
shorter [16]. The latter was proposed to be the result of 
hyperinflation-induced diaphragm shortening. Interest­
ingly, diaphragms from patients with moderate-to-severe 
COPD were found to be three times more susceptible to 
additional sarcomere disruption when breathing against 
inspiratory loads compared to non-COPD patients [20]. 
In line with these findings, recent data from a post mortem 
study in severe COPD patients reveal that acute-on- 
chronic increase in ventilatory loading induced extensive 
diaphragm injury and collagen accumulation [48]. 
Whereas intracellular, sarcomeric, injury in COPD dia­
phragm is evident, the membrane and the membrane- 
associated proteins, which are essential for force transmis­
sion to adjacent fibers, appear intact [75]. Together, these 
data indicate that sarcomeric injury is more pronounced 
in COPD diaphragm and increases with progression of 
the disease.
F ig u re 5
Electronmicroscopic photograph showing areas o f normal 
(A) and disrupted (B) sarcomeres in a diaphragm sample 
from  a patient w ith moderate-severe COPD. N ote the dis­
ruption and even absence o f A- and I-bands. Reproduced 
from  Orozco-levi et al. [20] w ith permission.
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In general, muscle injury is followed by an inflammatory 
response and subsequent regeneration. However, previ­
ous studies found no evidence of inflammatory cells in 
the diaphragm of patients with COPD, although injury 
was evident, suggesting an altered response to injury 
[8,20]. Muscle degeneration is followed by the activation 
of a muscle repair or regeneration process in which satel­
lite cell activation is an important step [70]. Activated sat­
ellite cells proliferate and differentiate to new myofibers. 
These newly formed fibers express embryonic/neonatal 
forms of myosin heavy chain [70]. However, preliminary 
data from our lab indicate that diaphragm satellite cell dif­
ferentiation into myotubes is impaired in COPD [76]. 
Also, Nguyen et al. [37] found lower expression of embry­
onic/neonatal myosin heavy chains in the diaphragm 
from COPD patients compared to non-COPD patients, 
and similar findings were reported in a preliminary study 
from our lab [77]. Finally, in an animal model of COPD, 
there was evidence of decreased MyoD and elevated 
inhibitor of differentiation protein 2 (Id2) levels in dia­
phragm muscle [78], which may impair satellite cell dif­
ferentiation, and thus its regenerative capacity. Together, 
these data suggest a non-adequate response to diaphragm 
injury in patients with COPD.
Oxidative and nitrosative stress
Oxidative and nitrosative stress reflect an imbalance 
between the production and scavenging of free radicals. 
Free radicals are molecules with at least one unpaired elec­
tron in their outer orbital. Since electrons are usually more 
stable when paired, radicals are more reactive than non­
radicals. In vivo, free radicals can be divided into oxygen- 
and nitrogen-centred free radicals, such as superoxide 
anion and nitric oxide, respectively. Sources for free radi­
cals in striated muscle include the mitochondrial electron 
transport chain, xanthine oxidase, neutrophils and nitric 
oxide synthases. Striated muscles generate free radicals at 
rest and production increases during contractile activity 
[79,80]. Their high reactivity makes it technically 
extremely complex to measure free radical levels inside 
muscle fibers. Therefore, in general, oxidative stress is 
determined indirectly by measuring the levels of oxidized 
proteins and/or lipids.
A recent study by Barreiro et al. [17] was the first to dem­
onstrate increased oxidative stress in the diaphragm of 
patients with severe COPD. They reported higher protein 
carbonyl groups and hydroxynonenal protein adducts, 
both markers of protein oxidation. Importantly, the dia­
phragmatic levels of protein oxidation showed a strong 
negative correlation with respiratory muscle strength. In 
the diaphragm of moderate COPD patients no signs of 
oxidative stress were present. In contrast to oxidative 
stress, nitrosative stress was not elevated in COPD dia­
phragm [17]. This was supported by unchanged protein
tyrosine nitration levels in the diaphragm of these 
patients.
Diaphragm versus peripheral muscles in COPD
One of the most remarkable alterations in COPD muscle 
is the fiber type shift that occurs in opposite directions in 
the diaphragm and peripheral muscles. Whereas the fiber 
type shift in the diaphragm resembles that associated with 
endurance training, adaptation of the limb muscles is 
characterized by a shift towards more fatigable, glycolytic 
type II fibers in severe COPD [81-84]. The changes in fiber 
type composition of peripheral muscles in COPD corre­
late with the reduced activity of oxidative enzymes in 
those muscles [85,86]. A study by Doucet et al. was the 
first to investigate fiber type proportions in the diaphragm 
and a limb muscle within the same patients with mild-to- 
moderate COPD. They found a fiber type shift in the dia­
phragm, whereas a fiber type shift in limb muscles was 
absent in these patients [19]. Apparently, fiber type shifts 
in the diaphragm occur earlier in the disease process than 
the changes in the limb muscles. In addition, several other 
abnormalities associated with COPD are specific for 
peripheral muscles or the diaphragm. For instance, in con­
trast to the diaphragm, peripheral muscles in COPD asso­
ciated with low body-mass-index show accelerated 
apoptosis and inflammatory changes [87]. Also, whereas 
diaphragm injury is a common feature in severe COPD, 
profound peripheral muscle injury has not been reported.
On the other hand, atrophy appears to be a common fea­
ture in both the diaphragm and peripheral muscles of 
COPD patients [81,88]. Also, similar to the diaphragm, 
the peripheral muscles in COPD are exposed to oxidative 
stress [89-92]. Nitrosative stress, however, appears to be 
more specific to the peripheral muscles than the dia­
phragm, and was proposed to be the result of increased 
activity of neuronal nitric oxide synthase in peripheral 
muscles of COPD patients [92-94].
It should be noted that the concept of peripheral muscles 
needs some differentiation. In general, the structure and 
function of the upper limb muscles appears to be less 
affected in COPD, presumably due to sustained activity 
during daily activities, whereas muscles from the lower 
limbs show more pronounced changes as a result of pro­
gressive deconditioning [95].
Genesis o f  a pathophysiological concept
The fiber type shift towards more oxidative type I fibers 
may initially be regarded as beneficial as it renders the 
overloaded COPD diaphragm more resistant to fatigue 
[15]. In fact, contractile fatigue is an uncommon event 
after exhaustive exercise in severe COPD [5,29,96]. How­
ever, the loss of myosin and force generating capacity in 
diaphragm single fibers, and the increased sarcomeric
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injury and oxidative stress, constitute maladaptive altera­
tions in the diaphragm of these patients [8,14,17,18,20], 
and have been suggested to greatly impair diaphragm 
function in vivo [14,17]. Together, these findings consti­
tute a cellular and molecular basis for the the notion that 
strength and not fatigue is the main limiting factor for in 
vivo respiratory muscle performance in COPD.
The strength of the diaphragm is strongly dependent on 
its contractile protein content. Recent data suggest that 
accelerated protein degradation via the ubiquitin-proteas- 
ome pathway contributes to loss of myosin in COPD dia­
phragm, and constitutes an initial step in the pathogenesis 
of diaphragm weakness in these patients. Chamberlain 
[97] addressed the role of selective degradation of myosin 
by the ubiquitin-proteasome pathway in cachexia [98]. 
Preferential loss of myosin would increase the average dis­
tance between myosin and actin filaments, inducing 
reduction of fiber size later in the course of the disease to 
restore filament lattice spacing needed for optimal con­
tractile function [97]. Indeed, loss of myosin precedes 
reduction of fiber cross sectional area in COPD dia­
phragm [18]. Although speculative, these findings sup­
port the hypothesis that, in mild-to-moderate COPD, loss 
of myosin is an initial, but functional important, step in 
diaphragm muscle fiber atrophy, as observed in severe 
COPD.
The giant protein titin might also be involved in dia­
phragm atrophy in COPD. The passive-elastic properties 
of titin are essential for maintaining structural and 
mechanical stability of the sarcomere during activation 
[43,99]. However, recent studies indicate that titin is an 
important player in the maintenance of striated muscle 
mass as well [100]. Titin functions as a stretch sensor with 
titin-based stiffness regulating muscle remodelling and 
gene expression, through a signaling pathway linking 
activity of titin's kinase domain to nuclear transcriptional 
activity [100]. Reduced mechanical strain on the titin 
kinase domain resulted in down-regulation of muscle- 
specific gene transcription, and was suggested to cause 
loss of contractile protein and muscle weakness in 
patients with hereditary myopathy with early respiratory 
failure [100]. We hypothesize that the reduced stiffness of 
titin in the diaphragm of mild-to-moderate COPD 
patients reduces its kinase domain activity, thereby induc­
ing loss of signaling between titin and the nucleus, result­
ing in decreased transcription of muscle-specific genes. 
This could affect the production of contractile proteins, 
and contribute to the loss of myosin in the diaphragm of 
these patients, especially since diaphragm protein turno­
ver might be elevated.
The increased susceptibility of the COPD diaphragm to 
inspiratory loading-induced sarcomeric injury appears to
be an important finding as it suggests that during exacer­
bations of COPD, when patients experience acute dia­
phragm loading, the diaphragm may develop additional 
injury. This could compromise diaphragm strength even 
more and consequently result in respiratory failure. 
Indeed, COPD patients experiencing acute-on chronic res­
piratory loading have extensive diaphragm fiber injury 
and fibrosis[48]. Moreover, the increased susceptibility to 
injury implies that, although the sarcomeric ultrastructure 
appears intact during electronmiscroscopical examina­
tion, the structural integrity of the sarcomere is, in fact, 
weakened. Reduced stiffness of titin in COPD diaphragm 
might play a role, as it could induce structural instability 
of sarcomeres, leading to misalignment of myosin fila­
ments and inability of the muscle fiber to resist sarcomere 
length inhomogeneity during activation. This overstretch­
ing of sarcomeres could contribute to the sarcomeric 
injury observed in the diaphragm of patients with severe 
COPD. In addition, the elevated levels of oxidized sarco- 
meric proteins in the diaphragm of patients with severe 
COPD might contribute to the increased susceptibility to 
diaphragm injury. Oxidized proteins have impaired struc­
tural integrity and function, and are known substrates for 
degradation via the ubiquitin-proteasome pathway [101]. 
These subtle structural modifications might be already 
present in patients with mild-to-moderate COPD, and 
play a role in the observed contractile protein dysfunction 
and the pronounced loss of myosin by accelerating ubiq- 
uitin-proteasome-mediated proteolysis. However, this is 
not supported by previous findings in moderate COPD 
patients, indicating similar levels of oxidized diaphragm 
proteins compared to non-COPD patients [17]. The detec­
tion of oxidatively modified proteins is, however, depend­
ent on the sensitivity of the assays to measure such 
damage [102]. Therefore, future studies using highly sen­
sitive proteomic analysis could resolve this issue. In 
healthy striated muscle, upon injury a rapid and extensive 
repair process is initiated to prevent loss of muscle mass. 
The fact that COPD diaphragm displays impaired regener­
ative processes, although injury is evident, suggests that 
impaired regeneration is involved in diaphragm atrophy.
The knowledge regarding diaphragm protein synthesis in 
COPD is very limited. Therefore, a major challenge for 
future studies will be to evaluate the relative contributions 
of protein degradation and synthesis pathways to the loss 
of contractile protein content in COPD diaphragm.
Identifying initial triggers leading to diaphragm weakness 
in COPD
Little is known regarding the etiology of cellular and 
molecular changes in COPD diaphragm. Therefore, a 
major challenge for future studies will be to identify the 
triggers responsible for the observed changes in the COPD 
diaphragm. This is especially challenging since several
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adaptations are already present early in the course of the 
disease. Mechanisms that might be involved include non- 
systemic factors, such as increased diaphragm loading due 
to pulmonary obstruction, and sytemic factors, such as 
systemic inflammation. However, no studies have 
reported systemic changes in patients with mild-to-mod- 
erate COPD. Also, if a systemic etiology is proposed, alter­
ations in the diaphragm and peripheral muscles are 
expected to share a high degree of similarity and, to a cer­
tain extent, develop simultaneously. However, the dia­
phragm and peripheral muscles appear differentially 
affected in COPD, and the diaphragmatic alterations 
appear to precede the peripheral muscle changes. There­
fore, at early onset of the disease, most likely other factors 
are involved in the etiology of diaphragm weakness.
A potential trigger for the diaphragmatic changes in 
COPD patients is elevated contractile activity of the dia­
phragm. Loaded breathing is known to impair diaphragm 
contractility in healthy humans [103]. It was proposed 
that free radicals were involved since treatment with N- 
acteyl-cysteine, a molecule with antioxidant properties, 
attenuated diaphragm dysfunction in these subjects [103]. 
In patients with severe COPD, diaphragm loading is 
increased [ 104], and recent data suggest oxidative stress in 
the diaphragm of these patients. Very little is known about 
diaphragm loading in patients with only mild-to-moder- 
ate COPD. Markers for oxidative stress were not elevated 
in the diaphragm of these patients, but oxidative protein 
modification could be too subtle for detection with the 
applied assays. The fiber type shift towards type I fibers in 
some patients with mild-to-moderate COPD does suggest 
elevated contractile activity of the diaphragm in these 
patients. With this in mind, we stress the importance of 
future studies aimed at evaluating diaphragm contractile 
activity in patients with mild or moderate COPD. The 
obtained data should indicate whether or not increased 
diaphragm loading might play a role in the development 
of diaphragm weakness in COPD.
Cytokines promote striated muscle injury, impair contrac­
tile protein function [105] and stimulate proteolysis 
through the ubiquitin-proteasome pathway in vitro [106­
108]. Circulating cytokines are proposed to initiate 
cachexia-associated muscle wasting by selective targeting 
myosin [97]. At rest, circulating levels of cytokines are ele­
vated in COPD, but only in a subgroup of severe COPD 
patients [109-111]. However, physical exercise induces an 
exaggerated systemic inflammatory and oxidative 
response in patients with moderate COPD [112]. This 
abnormal response could be harmful by inducing skeletal 
and diaphragm muscle changes. It would be interesting to 
know if this abnormal exercise-induced inflammatory 
response is also present in patients with mild-to-moderate 
COPD. In addition, the source for the exercise-induced
cytokines are yet to be determined. They have been attrib­
uted to bronchial inflammation, however, recent data 
indicate differential regulation of the cytokine response in 
induced sputum and plasma in COPD patients [113], 
which may suggest additional origins for COPD-associ- 
ated cytokinemia. The diaphragm provides an alternative 
candiate. Diaphragm loading induces expression of 
cytokines in rat diaphragm fibers [114] (for review see 
Vasillakopoulos et al[115]). We speculate that the expres­
sion of cytokines is increased in the diaphragm of patients 
with mild-to-moderate COPD, contributing to the 
observed diaphragmatic changes by promoting sarcom- 
eric injury, and protein modification and degradation. 
Therefore, evaluation of the cytokine profile in the dia­
phragm of patients with mild or moderate COPD will 
increase our understanding of the etiology of the cellular 
and molecular changes in COPD diaphragm.
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